Klement MR, et al. - Experts evaluated the impact of perioperative dexamethasone on 90-day readmissions and the rates of clinically significant venous thromboembolic events (VTE) or readmission following total joint arthroplasty (TJA). The rate of clinically significant VTE and 90-day readmission were the primary outcomes. The secondary outcomes included wound complications, periprosthetic joint infection (PJI) and 90-day mortality. Findings did not suggest an association of a single, intraoperative, low-dose of dexamethasone with a reduction in clinically significant VTE but to lower 90-day readmission rates, it could be a safe and effective adjunct medication.